<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NOREPINEPHRINE BITARTRATE</span><br/>(nor-ep-i-nef'rin)<br/><span class="topboxtradename">Levarterenol, </span><span class="topboxtradename">Levophed, </span><span class="topboxtradename">Noradrenaline<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha- and beta-adrenergic agonist (sympathomimetic)</span><br/><b>Prototype: </b>Epinephrine<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Direct-acting sympathomimetic amine identical to body catecholamine norepinephrine. Acts directly and predominantly on alpha-adrenergic
         receptors; little action on beta receptors except in heart (beta<sub>1</sub> receptors). Vasoconstriction and cardiac stimulation; also powerful constrictor action on resistance and capacitance blood
         vessels.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Peripheral vasoconstriction and moderate inotropic stimulation of heart result in increased systolic and diastolic blood pressure,
         myocardial oxygenation, coronary artery blood flow, and work of heart. Cardiac output varies with systemic BP.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To restore BP in certain acute hypotensive states such as shock, sympathectomy, pheochromocytomectomy, spinal anesthesia,
         poliomyelitis, MI, septicemia, blood transfusion, and drug reactions. Also as adjunct in treatment of cardiac arrest.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Use as sole therapy in hypovolemic states, except as temporary emergency measure; mesenteric or peripheral vascular thrombosis;
         profound hypoxia or hypercarbia; use during cyclopropane or halothane anesthesia; pregnancy (category D), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension; hyperthyroidism; severe heart disease; older adult patients; within 14 d of <small>MAOI</small> therapy; patients receiving tricyclic antidepressants.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypotension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> Start with 812 mcg/min, titrate to maintenance dose of 24 mcg/min<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> Start with 2 mcg/min, titrate to maintenance dose of 0.1 mcg/kg/min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span>  Dilute a 4 mL ampule in 1000 mL of D5W or D5/NS. Do not use solution if discoloration or precipitate is present. Protect
                  from light.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Initial rate of infusion is 23 mL/min (812 mcg/min), then titrated to maintain BP, usually 0.51 mL/min (24
                  mcg/min). An infusion pump is used. Usually give at the slowest rate possible required to maintain BP. Constantly monitor
                  flow rate. Check infusion site frequently and immediately report any evidence of extravasation: blanching along course of
                  infused vein (may occur without obvious extravasation), cold, hard swelling around injection site. Antidote for extravasation
                  ischemia: Phentolamine, 510 mg in 1015 mL NS injection, is infiltrated throughout affected area (using syringe
                  with fine hypodermic needle) as soon as possible. If therapy is to be prolonged, change infusion sites at intervals to allow
                  effect of local vasoconstriction to subside. Avoid abrupt withdrawal; when therapy is discontinued, infusion rate is slowed
                  gradually.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Aminophylline,</b> <b>amobarbital,</b> <b>whole blood,</b> <b>cephapirin,</b> <b>chlorothiazide,</b> <b>chlorpheniramine,</b> <b>pentobarbital,</b> <b>phenobarbital,</b> <b>phenytoin,</b> <b>secobarbital,</b> <b>sodium bicarbonate,</b> <b>sodium iodide,</b> <b>streptomycin,</b> <b>thiopental.</b> <span class="incompattype">Y-site:</span> <b>Insulin,</b> <b>thiopental.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Restlessness, anxiety, <span class="speceff-common">tremors,</span> dizziness, weakness, insomnia, pallor, plasma volume depletion, edema, hemorrhage, intestinal, <span class="speceff-life">hepatic</span>, or renal <span class="speceff-life">necrosis</span>, retrosternal and pharyngeal pain, profuse sweating. <span class="typehead">CV:</span> Palpitation, hypertension, reflex bradycardia, <span class="speceff-life">fatal arrhythmias</span> (large doses), severe hypertension. <span class="typehead">GI:</span> Vomiting. <span class="typehead">Metabolic:</span> Hyperglycemia. <span class="typehead">CNS:</span> Headache, violent headache, <span class="speceff-life">cerebral hemorrhage</span>, convulsions. <span class="typehead">Respiratory:</span> Respiratory difficulty. <span class="typehead">Skin:</span> Tissue necrosis at injection site (with extravasation). <span class="typehead">Special Senses:</span> Blurred vision, photophobia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">alpha and beta blockers</span> antagonize pressor effects; <span class="classification">ergot alkaloids</span>, <b>furazolidone,</b> <b>guanethidine,</b> <b>methyldopa,</b> <span class="classification">tricyclic antidepressants</span> may potentiate pressor effects; <b>halothane,</b> <b>cyclopropane</b> increase risk of arrhythmias. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> Very rapid. <span class="typehead">Duration:</span> 12 min after termination of infusion. <span class="typehead">Distribution:</span> Localizes in sympathetic nerve endings; crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver and other tissues by catecholamine o-methyl transferase and monoamine oxidase. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor constantly while patient is receiving norepinephrine. Take baseline BP and pulse before start of therapy, then q2min
            from initiation of drug until stabilization occurs at desired level, then every 5 min during drug administration.
         </li>
<li>Adjust flow rate to maintain BP at low normal (usually 80100 mm Hg systolic) in normotensive patients. In previously
            hypertensive patients, systolic is generally maintained no higher than 40 mm Hg below preexisting systolic level.
         </li>
<li>Observe carefully and record mental status (index of cerebral circulation), skin temperature of extremities, and color (especially
            of earlobes, lips, nail beds) in addition to vital signs.
         </li>
<li>Monitor I&amp;O. Urinary retention and kidney shutdown are possibilities, especially in hypovolemic patients. Urinary output is
            a sensitive indicator of the degree of renal perfusion. Report decrease in urinary output or change in I&amp;O ratio.
         </li>
<li>Be alert to patient's complaints of headache, vomiting, palpitation, arrhythmias, chest pain, photophobia, and blurred vision
            as possible symptoms of overdosage. Reflex bradycardia may occur as a result of rise in BP.
         </li>
<li>Continue to monitor vital signs and observe patient closely after cessation of therapy for clinical sign of circulatory inadequacy.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>